Montelukast: the add-on role with asthma and the honest warning

Montelukast is an asthma agent that is taken as a tablet and is popular precisely with children because no inhalation is necessary. But exactly here an honest look is worthwhile: montelukast is no emergency agent and as a rule also not the most important basic medicine but a supplement. And there is a serious warning on mental side effects that many portals let drop under the table. This guide explains understandably which role montelukast really plays in asthma therapy and what the FDA warning means. It does not replace medical advice but helps you classify the agent and speak well informed with your practice. Because anyone who understands what montelukast is meant for and what not can support the treatment and, in doubt, ask the right questions.

See more detail

At a glance

  • Montelukast is a leukotriene receptor antagonist that treats asthma and allergies anti-inflammatorily.
  • It is an add-on medicine, mostly supplementary to inhaled corticosteroids, and as a rule does not replace them.
  • Montelukast is no emergency agent and does not work with acute shortness of breath.
  • The FDA ordered in 2020 a boxed warning on possible neuropsychiatric side effects.
  • Watch out for changes of mood, sleep and behaviour, especially with children, and address them medically.

What is montelukast and how does it work?

Montelukast belongs to the group of leukotriene receptor antagonists, a class of asthma agents of its own. To understand its effect, a look at the processes with asthma and allergies helps. When the airways react to a stimulus such as allergens, the body releases messengers. An important group of these messengers are the so-called leukotrienes. They ensure that the muscle of the bronchi contracts, that more viscous mucus is formed and that the airways swell and become inflamed. The result are the typical asthma complaints such as cough, tightness and shortness of breath. With an allergy quite similar processes run, for example at the nasal mucosa, which explains the runny or blocked nose with hay fever.

Exactly here is where montelukast intervenes. It specifically blocks the docking points to which these leukotrienes normally bind, the so-called leukotriene receptors. If these receptors are occupied and blocked, the leukotrienes can no longer unfold their effect. As a result the bronchi become less easily narrow, less mucus is formed, and the inflammation of the airways recedes. Montelukast therefore works anti-inflammatorily and preventively by dampening a part of the excessive reaction. It intervenes at a different place than cortisone and supplements its effect instead of repeating it. A practical advantage is that it is taken once a day as a tablet, entirely without inhalation, which is why it is also frequently used with children. Montelukast is prescription only. Precisely because it is so easy to take, it is sometimes seen as an uncomplicated alternative to the bothersome inhaling. This convenience must, however, not obscure that it has a certain, limited role in the therapy and carries a warning that one should know.

Preventive, not for the emergency

Montelukast works preventively by slowly dampening the inflammation and hypersensitivity of the airways over time. It does not work immediately and does not widen the bronchi acutely. Therefore it is no emergency agent: with an acute asthma attack with sudden shortness of breath it does not help; for this you need your fast-acting emergency spray. Montelukast one takes regularly for the long-term treatment, while the emergency spray stays reserved for the acute case. These two roles must not be confused. Anyone who would replace the emergency spray with the tablet would stand without quick help in an emergency.

Understanding the add-on role with asthma

A common misunderstanding is that montelukast is an independent main medicine against asthma. In fact, it mostly has in the guidelines a different, clearly defined and rather supporting role: that of a supplementary medicine, in technical jargon add-on. The most important anti-inflammatory basic medicine with asthma are the inhaled corticosteroids, that is the cortisone sprays. They work directly in the airways and are the cornerstone of the long-term therapy. Without this basis, asthma cannot in most cases be reliably controlled, which is why it stands in first place. Montelukast mostly comes into play when this inhaled basic therapy alone is not enough to control the asthma well. It is therefore not the first agent one uses with newly diagnosed asthma but a reinforcement when the basic treatment still leaves gaps.

In this add-on role montelukast supplements the effect of the sprays but as a rule does not replace them. The advantage: it intervenes at a different place of the inflammation cascade than the cortisone and can thereby bring an additional control. Two agents with different points of attack often supplement each other better than if one keeps increasing the dose of a single agent. There are, however, situations in which montelukast can also serve as an alternative, for example with very mild asthma or when the inhalation is difficult for certain reasons, always after medical weighing-up. With small children, for example, who do not yet cope well with an inhaler, the tablet can be a practical solution. Montelukast has a particular strength with two constellations: with exercise asthma, that is when physical exertion triggers the complaints, and when an allergic rhinitis exists at the same time, because it works on both problems. Precisely with exercise asthma, which affects above all younger and athletically active people, the preventive intake can help to reduce complaints during exertion. Important remains: montelukast is a building block in an overall concept that the medical practice puts together individually. This classification as a supplement rather than as a main agent is no disadvantage but simply corresponds to what the guidelines recommend. Anyone who understands this has realistic expectations and does not accidentally replace the important cortisone spray with the more convenient tablet, which would endanger the asthma control.

Asthma therapy in overview

With asthma several medicines often come together: basic spray, emergency spray and sometimes a supplement like montelukast. brite helps you keep the overview and be reminded of the regular intake.

Try brite for free

Free · ad-free · GDPR-compliant

The FDA warning: what many portals keep quiet

Let us now come to a point that many guide pages mention astonishingly briefly or not at all but that absolutely belongs to an honest explanation: the warning on neuropsychiatric side effects. The US drug authority FDA ordered in the year 2020 the strongest warning level, a so-called boxed warning, for montelukast. Such a framed warning is the clearest safety marking that a medicine can carry in the USA, and it was imposed here because of possible effects on psyche and behaviour. That an authority reaches for this strongest means shows that the topic must be taken seriously, even if the side effects do not affect everyone.

These possible neuropsychiatric reactions include sleep disturbances and nightmares, mood swings, irritability and restlessness, anxiety and depressive mood. In rarer cases hallucinations, conspicuous behaviour and suicidal thoughts were also reported. Important is that these reactions can occur not only at the start but also with delay over the course of the treatment. This makes it harder to connect them with the medicine, which is why the knowledge about it is so valuable. The FDA expressly recommended using montelukast only with restraint with mild complaints such as a pure allergic rhinitis when other, well-tolerated treatments are available, because here the risk possibly outweighs the benefit. European authorities too, such as the drug commission of the German medical profession and the British MHRA, have pointed to this risk and recommend actively informing patients and parents about it. This warning is no reason for panic but a clear reason to handle the agent well informed and attentively. Many people take montelukast without mental side effects, and for them it can be a valuable building block of asthma therapy. Decisive is that one knows the possible side effect, does not trivialise it and reacts early when mood, sleep or behaviour change. Exactly this honest explanation is missing on many guide pages that praise the agent only as a harmless tablet without inhalation.

Watch out for mood, sleep and behaviour

Watch out during the intake of montelukast for changes of mood, sleep and behaviour, with yourself and especially with your child. Warning signs are unusual irritability, restlessness, nightmares, dejection, anxiety or conspicuous behaviour, in rare cases thoughts of self-harm. If such symptoms occur, seek medical advice promptly so that benefit and risk are weighed up anew. Do not stop montelukast abruptly on your own but discuss the further procedure medically. Often the therapy can then be switched to a better-tolerated alternative. With acute thoughts of self-harm, get help immediately.

Tolerability, further side effects and stopping

Apart from the neuropsychiatric reactions, montelukast is well tolerated by many people. The more common side effects are mostly mild and include headache, abdominal pain, diarrhoea, nausea, infections of the upper airways and occasionally a skin rash. Nevertheless the intake should take place consciously and after medical weighing-up, precisely because the agent is often used over a long time and also with children. A good explanation about possible mental side effects belongs for many experts today to a responsible prescription. This way one can counteract early if complaints occur instead of not connecting them with the medicine.

With hay fever too the weighing-up plays a role. Montelukast is indeed approved for the treatment of allergic rhinitis, but precisely with a pure, mild allergy authorities advise considering first other, well-tolerated agents such as antihistamines or cortisone-containing nasal sprays. Montelukast is sensible above all when asthma and allergy occur together. In this case a single agent can work on both problems, which simplifies the treatment and can save an additional medicine. As regards stopping it applies: even if montelukast is no emergency agent, you should not stop it without consultation because that can worsen the asthma control. A stably adjusted asthma can get out of balance again through a thoughtless stop. If you want to stop because of side effects, discuss this with your medical practice so that the therapy can be safely adjusted and the inhaled basic treatment reviewed. This way it is avoided that through an uncontrolled stop the asthma suddenly gets worse. Frequently a well-tolerated solution can be found together, be it through a different active ingredient combination or an adjusted basic therapy.

Role What montelukast is and what not
Mechanism leukotriene receptor antagonist, anti-inflammatory
Position in the therapy mostly add-on to the cortisone spray, no replacement
In the acute attack not effective, no emergency agent
Particular strength exercise asthma, accompanying allergic rhinitis
Important warning possible neuropsychiatric side effects
brite App

Asthma medicines and symptoms in view

Precisely with an asthma therapy of several agents and an active ingredient with a warning, a clear overview helps. Anyone who keeps basic spray, emergency spray and supplementary agent apart avoids dangerous mix-ups. brite helps you manage your medicines, be reminded of the daily intake and record changes such as mood or sleep that you want to address medically.

  • Clear, digital medication plan
  • Reminders for the daily intake
  • Record changes for the next appointment
Start for free now
brite App, medication plan and interaction check

In sum, montelukast is a useful asthma agent with a clearly defined role that one should know: it is a supplement to the inhaled basic therapy, no emergency agent and as a rule no replacement for the cortisone spray. And it carries a serious warning on possible mental side effects that demands attentive accompaniment, especially with children. With asthma it is a building block alongside the basic spray, frequently together with budesonide as an inhaled corticosteroid. With allergic rhinitis, the benefit should be weighed particularly carefully against the risk. With this knowledge you can classify montelukast correctly and decide together with your medical practice whether and how it fits into your treatment.

Well prepared for the doctor's appointment

Add your medicines to brite for free and record changes of mood or sleep. This way you can at the appointment specifically speak about benefit, risk and possible alternatives.

Try for free

Free · ad-free · GDPR-compliant

Frequently asked questions about montelukast

Montelukast is an anti-inflammatory asthma agent from the group of leukotriene receptor antagonists. It blocks the docking points of the leukotrienes, that is of messengers that narrow the bronchi, form mucus and inflame the airways. As a result the airways become less easily narrow and inflamed. It is taken once a day as a tablet, without inhalation, and is prescription only.
No. Montelukast works preventively and dampens the inflammation, but it does not work immediately and does not widen the bronchi acutely. With an acute asthma attack with shortness of breath you need your fast-acting emergency spray. Never stop the emergency spray and do not replace it with montelukast. Montelukast is an agent for the long-term treatment.
Add-on means supplement. The most important basic medicine with asthma are inhaled corticosteroids, that is cortisone sprays. Montelukast is mostly given additionally when the inhalation alone is not enough, and supplements their effect but as a rule does not replace them. It is particularly sensible with exercise asthma and accompanying allergic rhinitis.
The FDA ordered in 2020 a boxed warning, the strongest warning level, for montelukast, because of possible neuropsychiatric side effects such as sleep disturbances, mood swings, anxiety, depressive mood and rarely hallucinations or suicidal thoughts. These can also occur with delay. With mild complaints such as pure allergic rhinitis, restraint is recommended.
Watch out for changes of mood, sleep and behaviour, with yourself or your child, for example irritability, restlessness, nightmares, dejection or anxiety. If such symptoms occur, seek medical advice promptly so that benefit and risk are weighed up anew. Do not stop montelukast on your own. With children, parents should be informed about this possible side effect.
The more common side effects are mostly mild, for example headache, abdominal pain, diarrhoea, nausea, infections of the upper airways and sometimes skin rash. Many tolerate montelukast well. Because of the often long intake, it should take place consciously and after medical weighing-up. With burdening side effects or mental changes, seek medical advice.
Yes, montelukast is also approved for the treatment of allergic rhinitis, often together with the asthma treatment. With a pure, mild allergy, however, authorities advise considering first other agents such as antihistamines or cortisone-containing nasal sprays, because the FDA warning also refers to this. It is sensible above all when asthma and allergy occur together.
Do not stop montelukast on your own without consultation, even if it is no emergency agent. As part of the long-term treatment, a sudden stop can worsen the asthma control. If you want to stop, for example because of side effects, discuss this medically so that the therapy can be adjusted and the basic treatment with the inhaler reviewed.
Montelukast is prescription only in Germany. It is also frequently used with children because it is taken once a day as a tablet or granules and no inhalation is necessary. Precisely with children, the explanation about possible neuropsychiatric side effects is important: parents should watch out for changes of mood, sleep and behaviour. Whether montelukast fits is decided by the medical practice after weighing-up of benefit and risk.

Related topics

Sources

  • Gelbe Liste: montelukast, mechanism (CysLT1 receptor), use
  • PharmaWiki: montelukast, leukotriene antagonist, side effects
  • Apotheke Adhoc: boxed warning of the FDA for montelukast (neuropsychiatric reactions)
  • Deutsches Ärzteblatt / AkdÄ: neuropsychiatric symptoms with montelukast
  • Medscape: FDA warning, restraint with mild allergic rhinitis
  • ifap / MHRA: reminder of neuropsychiatric side effects, also delayed

This guide serves general information and does not replace medical advice, diagnosis or treatment. It contains no dosage recommendation. Montelukast is prescription only and no emergency agent. Do not stop it on your own. Watch out for changes of mood, sleep and behaviour and seek medical advice with such symptoms. This text names mental side effects that can be burdening. With acute thoughts of self-harm, turn immediately to medical help or a counselling service.